Rapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor models by Alexandra Eichten et al.
ORIGINAL PAPER
Rapid decrease in tumor perfusion following VEGF blockade
predicts long-term tumor growth inhibition in preclinical tumor
models
Alexandra Eichten • Alexander P. Adler • Blerta Cooper •
Jennifer Griffith • Yi Wei • George D. Yancopoulos •
Hsin Chieh Lin • Gavin Thurston
Received: 19 June 2012 / Accepted: 23 November 2012 / Published online: 13 December 2012
 The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract Vascular endothelial growth factor (VEGF) is a
key upstream mediator of tumor angiogenesis, and block-
ade of VEGF can inhibit tumor angiogenesis and decrease
tumor growth. However, not all tumors respond well to
anti-VEGF therapy. Despite much effort, identification of
early response biomarkers that correlate with long-term
efficacy of anti-VEGF therapy has been difficult. These
difficulties arise in part because the functional effects of
VEGF inhibition on tumor vessels are still unclear. We
therefore assessed rapid molecular, morphologic and
functional vascular responses following treatment with
aflibercept (also known as VEGF Trap or ziv-aflibercept in
the United States) in preclinical tumor models with a range
of responses to anti-VEGF therapy, including Colo205
human colorectal carcinoma (highly sensitive), C6 rat
glioblastoma (moderately sensitive), and HT1080 human
fibrosarcoma (resistant), and correlated these changes to
long-term tumor growth inhibition. We found that an
overall decrease in tumor vessel perfusion, assessed by
dynamic contrast-enhanced ultrasound (DCE-US), and
increases in tumor hypoxia correlated well with long-term
tumor growth inhibition, whereas changes in vascular gene
expression and microvessel density did not. Our findings
support previous clinical studies showing that decreased
tumor perfusion after anti-VEGF therapy (measured by
DCE-US) correlated with response. Thus, measuring tumor
perfusion changes shortly after treatment with VEGF
inhibitors, or possibly other anti-angiogenic therapies, may
be useful to predict treatment efficacy.
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Introduction
Vascular endothelial growth factor (VEGF) plays a key
role in physiological and pathological angiogenesis,
including tumor angiogenesis [1]. Therefore, a number of
agents that inhibit VEGF signaling have been developed
and tested in clinical trials [2, 3]. Bevacizumab, a VEGF
specific antibody that prevents receptor binding and acti-
vation, slowed tumor progression and provided survival
benefits in several human tumor types when used in com-
bination with chemotherapy. In addition, several small
molecule inhibitors of VEGF receptor tyrosine kinase
activity provided benefit in various cancers [4–6]. In pre-
clinical models, VEGF inhibition results in reduced tumor
growth, decreased microvessel density (MVD) and nor-
malization of tumor vessel morphology in a wide range of
tumor types [7, 8]. Similar MVD reductions were also
reported in clinical studies of colorectal tumors sampled
shortly after bevacizumab treatment [9].
Despite clear evidence for tumor vessel loss following
VEGF inhibition, the functional consequences on tumor
blood flow and oxygenation are not entirely clear. Naı¨vely,
one might expect that vessel loss would result in decreased
tumor perfusion. However, more detailed considerations
suggested the opposite, namely, that tumor vessel pruning
and ‘‘normalization’’ may lead to decreased intra-tumoral
pressure, increased tumor perfusion, and consequently
decreased tumor hypoxia [10]. Indeed, some preclinical
studies indicate increased tumor perfusion after VEGF
blockade [11, 12]. In contrast, other studies have reported
increased tumor hypoxia and decreased perfusion in
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preclinical models and non-small cell lung cancer (NSCLC)
patients [13–15]. Thus, the functional consequences of anti-
VEGF therapy are not clear, even in preclinical tumor
models.
To add to the complexity, not all tumors within a given
tumor type respond equally well to anti-VEGF therapy. For
example, in glioblastoma patients treated with a small
molecule kinase inhibitor (cediranib), approximately 60 %
of tumors displayed changes in dynamic contrast-enhanced
magnetic resonance imaging (DCE-MRI) signals indicative
of a response to anti-VEGF therapy, whereas the remaining
40 % did not [16]. Despite much effort, predicting which
tumors will respond to anti-VEGF therapy, or how long-
term tumor growth response is related to vascular changes,
has been difficult. For instance, it is unknown whether
tumors with the largest MVD reduction show the greatest
tumor growth inhibition (TGI). Further, tumor vessel fea-
tures rendering them sensitive, or resistant, to VEGF
inhibition are not well understood. Ultimately, predictive
biomarkers based on mechanistic differences in tumor cells
and tumor blood vessels are needed.
To begin to address these issues, we characterized initial
responses of tumor vessels to VEGF blockade in preclinical
tumors with a range of responses to anti-VEGF therapy
(sensitive, moderately responsive, and resistant). For these
studies, we used aflibercept (also known as VEGF Trap or
ziv-aflibercept in the United States), a recombinant fusion
protein that potently binds all isoforms of human and
murine VEGF-A, VEGF-B and Placental Growth Factor
(PlGF). Tumor bearing mice were treated with aflibercept,
and tumors were analyzed for rapid (within 3 days) chan-
ges in molecular (gene expression), morphologic (MVD)
and functional (vascular perfusion, tumor hypoxia) tumor
vessel properties. These changes were then compared to
aflibercept-mediated longer-term tumor growth effects.
Using this approach, we observed that functional changes
correlated well with the overall level of TGI, whereas
molecular or morphological changes showed a poor cor-
relation. These findings suggest that changes in functional
parameters, such as tumor perfusion and hypoxia, may be
good predictors of long term growth inhibition.
Materials and methods
In vivo tumor studies
Animal studies were performed in accordance with
Regeneron’s Institutional Animal Care and Use Committee
guidelines. Tumor cells were obtained from the American
Type Culture Collection (ATCC), except for the PC3 M
line, which was obtained from the NCI, DCT Tumor
Repository, NCI-FCRF, Frederick, MD. 1 9 106 Colo205
human colon carcinoma, 1 9 106 C6 rat glioblastoma,
2 9 106 HT1080 human fibosarcoma, 1 9 106 A431 human
squamous cell carcinoma, 1 9 106 786-0 human renal cell
carcinoma, 5 9 105 MMT murine mammary carcinoma,
1 9 106 PC-3 M metastasis-derived variant of human
prostate adenocarcinoma PC-3 and 1 9 106 LLC murine
Lewis lung carcinoma cells were grown s.c. in male
CB.17/SCID mice (Taconic). When tumors reached
approximately 100 mm3, mice were treated by s.c. injection
with hFc (control protein, 25 mg/kg) or a maximally effec-
tive anti-tumor dose of aflibercept [17] (VEGF Trap, ziv-
aflibercept, 25 mg/kg) (# mice per treatment group: n = 5–7
tumor growth; n = 4–5 IHC; n = 3–4 TaqMan; n = 8–24
micro-ultrasound; n = 5–10 FITC-lectin flow cytometry).
For long-term studies treatments occurred 2 9 per week.
Mice were monitored for tumor growth and overall health.
HypoxyProbe-1 (Chemicon; 60 mg/kg) was injected i.p. 1 h
prior to sacrifice. Tumors were harvested:* tumor in 4 %
paraformaldehyde, a cross-section in OCT, * tumor in
RNAlater. % Tumor Growth Inhibition (TGI) was calculated
as follows: [1 - ((Tfinal - Tinitial)/(Cfinal - Cinitial))]*100,
where T = aflibercept-treated tumor volumes and C =
control-treated tumor volumes at treatment start and after
10-14 day treatment (10 days: LLC, MMT; 14 days:
HT1080, Colo205, C6, A431, 786-0, PC-3 M). Tumor
growth curves are presented as mean ± standard error
of the mean (SEM).
Immunohistochemistry and image analysis
IHC on gelatin embedded tissue sections: Tissues were
fixed in 4 % paraformaldehyde for 72 h and embedded in a
4 % gelatin/PBS solution. Gelatin blocks were fixed in 4 %
paraformaldehyde overnight at 4 C, then transferred into a
30 % sucrose/PBS solution at 4 C until the blocks sunk
(*72 h). Tissue was cut into 80 lm sections, which were
stored in cryoprotectant (1 % Polyvinylpyrrolidone, 30 %
glycerol, and 30 % sucrose in NaPBS) at -20 C until
further use. For IHC detection of CD31 and HypoxyProbe
(pimonidazole), sections were treated as follows: 30 min in
0.3 % H2O2 at 4 C, 2 h in blocking solution (CD31: 0.3 %
Triton X100/4 % normal rabbit serum/1 % BSA/PBS;
HypoxyProbe: 0.3 % Triton X100/4 % normal horse
serum/1 % BSA/PBS) at RT followed by an overnight
incubation at 4 C with rat anti-murine CD31 Ab (1:150;
BD; MEC13.3) or a mouse anti-HypoxyProbe-1 antibody
(1:1,000; Chemicon) diluted in the respective blocking
solution containing 1 % serum. After five 3 min washes in
PBS, CD31 was detected with a biotinylated mouse-
adsorbed rabbit anti-rat antibody (1:150; Vector Labora-
tories;) and HypoxyProbe was detect with a biotinylated
horse anti-mouse antibody (1:500; Vector Laboratories;) in
a 2 h incubation at RT. Sections were subjected to an ABC
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reaction according to the manufacturers recommendations
(Vector Laboratories; ABC VectaStain Elite) for 1 h at RT
diluted in 1 % BSA in 50 mM PBS. After five 3 min
washes in PBS, antigens were revealed with 3,3’-diam-
inobenzidine (DAB, Sigma).
OCT embedded tumors were cut into 30 lm frozen sec-
tions. Tissue was air dried, 10 min fixed in acetone (-20 C),
avidin–biotin blocked (Vector), blocked in 2.5 % normal goat
serum/1 % BSA/PBS for 30–45 min (RT), incubated for 16 h
at 4 C with rat anti-murine CD31 Ab (1:50; BD) diluted in
0.5 9 block followed by a 45 min (RT) incubation with a
biotinylated anti-rat antibody (1:150; Vector). Antigens were
revealed with 3,3’-diaminobenzidine (DAB, Sigma).
For analysis photomicrographs were acquired at
2.5 9 magnification. Vessel density and hypoxia area were
determined using NIH image software as previously
described [18].
RNA preparation and TaqMan analysis
Total RNA was purified using RNeasy (Qiagen). RNA
quality and concentration were evaluated using a specto-
photometer (NanoDrop ND-1000). cDNA was synthesized
using 1 lg of total RNA and High Capacity RNA to cDNA
Mastermix Kit (ABI). Expression of various genes was
normalized to cyclophilin expression. TaqMan primer and
probe sequences are as follows:
Flow cytometry
Tumor bearing mice (C6 or HT1080 tumors, 100 mm3), or non-
tumor control mice, were treated s.c. with hFc (control protein,
25 mg/kg) or aflibercept (VEGF Trap, 25 mg/kg) 24 h prior to
tissue harvest. To label endothelial cells of functional vessels,
mice were i.v. injected with FITC-conjugated Lycopersicon
esculentum (tomato) lectin (2.0 mg/ml; Vector) 3 min prior to
tissue harvest. Single cell suspensions were prepared from
normal skin (n = 4, n = 2 no FITC-lectin), C6 tumors (n = 7
control or aflibercept, n = 4 no FITC-lectin) or HT1080 tumors
(n = 7 control or aflibercept, n = 3 no FITC-lectin) as
described previously [19] and endothelial cells were detected
using a PE-conjugated anti-CD31 Ab (1:200; BD). DAPI
(1 lg/ml; Invitrogen) was used to exclude dead cells. Data
acquisition: Beckman-Coulter MoFlo Legacy; data analysis:
FlowJo software (Tree Star). Data shown represent mean ±
standard error of the mean (SEM).
Dynamic contrast-enhanced micro-ultrasound
(DCE-micro US)
Animals were anaesthetized (isofluorane (3.0 %)/medical
air mixture), secured to heated platform and dehaired.
Ultrasound gel (Aquasonic, Parker Laboratories) provided
coupling interface between ultrasound probe and animal.
Image acquisition: Vevo2100 micro-ultrasound imaging
system (VisualSonics); contrast agent: MicroMarkerTM
(microbubbles, VisualSonics). Contrast agent was prepared
with a final concentration of 2 9 109 microbubbles/ml
saline and a 50 ll bolus was delivered via tail vein catheter
during image acquisition. Quantification of relative blood
volume, which represents tumor perfusion, was determined
by analysis of a 2D area representing the largest tumor
cross-section (Vevo2100 analysis software).
Statistical analyses
Statistical analyses were performed using Prism software.
Specific test include 2-way ANOVA with Bonferroni post
hoc test (tumor growth curves), 1-way ANOVA with
Bonferroni post hoc test (vessel density, gene expression
changes, hypoxia analysis) and Mann–Whitney test (micro-
ultrasound analysis). p values \0.05 were considered sta-
tistically significant.
Results
Vessel morphology changes in tumors with a range
of responses to aflibercept
Based on studies with a wide variety of murine tumor
models, three tumors that display a range of responses to
Gene Forward primer Reverse primer Probe sequence
mKcne3 AGACCTGGTACATGAGCCTCCAT CAAGTGACTGTGAAGGGTTGTGTT TGGGCAGTCTCATCCT
mNid2 CCGCTGTGGCCCTAATTCT TGCGGCATTCACACCTGTA TGTGTGTCAACTTGGTGGG
mCdh5 AATCGGGAGCATGCCAAGT TGGGCACCCCGTTGTC CCCGTGCTCATCTC
mTie1 AGCCTGAGCCCTTGAGTTACC AAAGTTGCCCTCCCCTATGAG TGGGAGGACATCACC
mRobo4 GCTAGGCGCTTTCCATCCA GCGGCTGCAGAGACTATCTGA TTGGCTGGAACCTC
mEsm1 TCTGGACTTTCCCTTCTTCCAG CTGTGTGGGAGGCAGAGGTC TGCAGCAGCCAAATCTCCCAGCA
mVegfA GTATGGCTGGCTGGGTCACT GTTTGATCCGCATGATCTGTAGAG ACCACTGTGATCTGC
mCyclophilin CGTGGGCTCCGTCGTC CCCTTCTTCTTATCGTTGGCC TTGCTGCCCGGACCCTCCG
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aflibercept were chosen for more detailed study. Colo205
tumors were potently growth inhibited (Fig. 1a), C6 tumors
showed an intermediate growth inhibition in response to
aflibercept treatment, with an initial growth delay followed
by restrained tumor growth (Fig. 1b). In contrast, HT1080
tumors showed no growth inhibition upon aflibercept
treatment (Fig. 1c). These differences in tumor response
were observed at a saturating dose of aflibercept (25 mg/kg
twice per week), thus the differences reflect inherent
responses to aflibercept and not merely different dose
responses.
We investigated the rapid effects of VEGF blockade on
the vasculature of these 3 tumor types. As revealed by
immunohistochemistry (IHC) for the vessel specific marker
CD31 in thick sections, untreated Colo205 and C6 tumors
have a significantly lower MVD (17 and 20 %, respectively)
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Fig. 1 Tumor growth and vascular response to aflibercept in
Colo205, C6 and HT1080 tumors. a–c Colo205, C6 and HT1080
xenografts (n = 5–7 each treatment group/tumor type) show different
levels of TGI in response to aflibercept treatment (black) compared to
control-treated tumors (grey): sensitive Colo205, moderately respon-
sive C6 and resistant HT1080. d–f Representative images of MVD
assessed by CD31 IHC in control and 24 h aflibercept-treated
Colo205, C6 and HT1080 tumors (80 lm gelatin sections). g–
i Quantitative analysis of vessel area density (%) in control and 8, 24
and 72 h aflibercept-treated Colo205, C6 and HT1080 tumors
(n = 4–5 each time point/tumor type). All experiments were repeated
at least twice; shown is an example experiment (n = 5–7 for each
treatment group (tumor growth data) or n = 4–5 for each time point
(MVD data)). Results shown represent means for tumor growth data
and mean ± standard deviation (SD) for MVD analysis. P \ 0.05*,
\0.01**, \0.001***, \0.0001**** by 2 way-ANOVA with Bonfer-
roni post hoc test (tumor growth data compared to control treated
tumor growth) and by 1 way-ANOVA with Bonferroni post hoc test
(MVD, each time point compared to control (0 time point))
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than HT1080 tumors (55 %) (Fig. 1d–f upper images; g–i
time point 0). Following aflibercept treatment, MVD rapidly
decreased in all tumor types, albeit to varying degrees
(Fig. 1d–f lower images; g–i). Quantitative analysis of rel-
ative MVD after aflibercept administration in comparison to
control-treated tumors revealed that Colo205 tumors lost 11,
32 and 54 % of their vasculature at 8, 24 and 72 h after
treatment, respectively. C6 tumors lost even more vessels
(28, 67 and 81 % at 8, 24 and 72 h after treatment, respec-
tively). Aflibercept resistant HT1080 tumors progressively
lost vessels after aflibercept treatment, albeit to a much lesser
degree (up to 29 % by 72 h), suggesting that the HT1080
tumor vasculature is only partially dependent on VEGF.
These results show that blockade of VEGF can cause rapid
loss of tumor vascularity, and further, that the vasculature in
different xenograft tumors varies in its dependence on
ongoing VEGF signaling.
Identification of two phases of gene expression changes
in tumor vessels following aflibercept treatment
To determine how morphological tumor vessel changes
manifest as molecular changes in gene expression, micro-
array analysis was performed on RNA from whole tumors
treated with aflibercept for 8, 24 and 72 h. Mouse and
human genes were assessed separately using mouse and
human specific gene chips (custom Agilent microarray).
Microarray analysis of mouse (host) genes in different
tumors implied a rapid and consistent decrease in expres-
sion of a number of genes specific to endothelial cells
[20–22] following aflibercept treatment. To confirm and
extend the microarray findings, six genes were analyzed for
expression changes in Colo205, C6 and HT1080 tumors
treated with aflibercept for 8, 24 and 72 h by TaqMan,
using primer pairs specific for murine mRNA. Gene
expression was normalized to cyclophilin expression
(similar results were obtained using GAPDH as a nor-
malization gene; data not shown). Close inspection of these
gene expression changes revealed two distinct temporal
patterns: ‘acute’ and ‘delayed’ response genes. The ‘acute’
set of genes decreased in expression rapidly after afliber-
cept treatment (8 h) and remained decreased (Fig. 2a–c,
black lines). Further, these ‘acute’ genes showed a large
absolute decrease in expression levels, dropping up to
85 %. Among the ‘acute’ genes were potassium voltage-
gated channel Isk-related subfamily gene 3 (Kcne3),
endothelial cell-specific molecule 1 (Esm1) and nidogen2
(Nid2). Because of their rapid decrease after VEGF
blockade (Fig. 2a–c, black lines), these ‘acute’ genes are
likely direct targets of VEGF signaling.
A second set of genes decreased in expression at 24 and
72 h after aflibercept treatment, but were not yet signifi-
cantly affected at the 8 h time point, thus showing a
‘delayed’ response (Fig. 2a–c, grey lines). Examples of
genes that displayed robust ‘delayed’ changes were
roundabout homolog 4 (Robo4), cadherin 5 (Cdh5) and
tyrosine kinase with immunoglobulin-like and EGF-like
domains 1 (Tie1). Other genes in this category included
platelet/endothelial cell adhesion molecule 1 (Pecam1 or
CD31) and intercellular adhesion molecule 2 (Icam2) (data
not shown), two commonly used IHC endothelial cell
markers [23, 24]. Thus, these ‘delayed’ genes may reflect a
decrease in overall tumor vascularity or endothelial cell
number. Changes in ‘delayed’ gene expression and MVD
(Fig. 1d–i) appeared to have similar trends in terms of both
timing and magnitude of decrease in different tumor types.
When the combined expression of the ‘delayed’ gene
changes was overlayed with MVD changes, comparable
patterns emerged for each tumor (Fig. 2d–f), suggesting
that ‘delayed’ gene changes can be used as markers for
changed MVD in tumors treated with VEGF inhibitors.
Decreased tumor perfusion following treatment
with aflibercept
To determine whether VEGF blockade also affected vessel
functionality, we assessed tumor vessel perfusion 24 h after
aflibercept administration using contrast-enhanced micro-
ultrasound. Analysis of 2-dimensional (2D) ultrasound data
revealed that perfusion of Colo205 and C6 tumors
decreased by 32 and 59 %, respectively (Fig. 3a, b, d, e). In
comparison, HT1080 tumor perfusion was not decreased at
24 h after aflibercept treatment (Fig. 3c, f). Interestingly,
although HT1080 tumors have a dramatically higher base-
line MVD (55 %; Fig. 1i) than C6 (20 %; Fig. 1h) or
Colo205 tumors (17 %; Fig. 1g), baseline perfusion in the
three tumor types was comparable (relative contrast inten-
sity values of 8–10; Fig. 3d–f, control), as was previously
shown for other tumor types [25]. These data suggest that a
smaller fraction of vessels are well perfused in HT1080
tumors compared to C6 or Colo205 tumors.
To further compare the relative amounts of perfused
vessels in C6 and HT1080 tumors, vessel perfusion was
assessed by another method, namely i.v. injection of
FITC-conjugated Lycopersicon esculentum tomato lectin
(FITC-lectin), which binds to the luminal surface of blood
endothelial cells (BECs, defined as CD31 positive) in func-
tionally perfused vessels. Following in vivo labeling, the
proportion of endothelial cells in the tumor and normal skin,
and the fraction of endothelial cells labeled by FITC-lectin
were both assessed by flow cytometry. For reference, BECs
from normal skin comprise 1.9 % of all skin cells, and 96 %
of the BECs in normal skin were labeled by FITC-lectin
(Fig. 3g, skin). As a further control, the same proportion of
BECs were found in skin and tumors of mice that were
injected with FITC-lectin versus those that were not injected,
Angiogenesis (2013) 16:429–441 433
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but virtually no BECs were found to be positive for FITC-
lectin in non-injected mice (Fig. 3g).
The number of BECs in untreated C6 tumors (0.8 % of
total cells) was significantly less than in HT1080 tumors
(2.2 %) (Fig. 3g). Of the BECs in untreated C6 tumors,
approximately 55 % were perfused (i.e., positive for FITC-
lectin). In contrast, only 18 % of the BECs in untreated
HT1080 tumors were perfused (Fig. 3g; Table 1). Thus,
despite more than a twofold difference in total BEC,
the fraction of BECs labeled by intravascular lectin
(FITC-positive BECs) was similar in C6 and HT1080 tumors
(0.40 vs. 0.43 % of total cells, respectively). This finding
corroborates our micro-ultrasound findings that untreated C6
and HT1080 tumors have similar levels of perfusion as
measured by micro-ultrasound (Fig. 3e, f, control), despite
dramatically different MVD (Fig. 1i, h, control).
Treatment with aflibercept (24 h) decreased the number
of BECs in C6 tumors to 0.5 % of total cells (*37 %
decrease) and to 1.6 % in HT1080 tumors (*28 %
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Fig. 2 Gene expression
analysis revealed two phases of
gene expression changes in
tumor vessels following
aflibercept treatment. a–c Gene
changes (TaqMan) upon VEGF
blockade occur in two distinct
patterns: ‘acute’ gene changes
occur in Kcne3, Esm1 and Nid2
(black), while ‘delayed’ gene
changes occur in Tie1, Cdh5
and Robo4 (grey) in Colo205,
C6 and HT1080 tumors after 8,
24 and 72 h aflibercept
treatment (n = 3–4 each time
point/tumor type) d–f Averages
of MVD changes (grey) and
averages of ‘delayed’ gene
expression changes (black)
show a corresponding pattern in
Colo205, C6 and HT1080
tumors after 8, 24 and 72 h
aflibercept treatment. All
experiments were repeated at
least twice; shown is an
example experiment for
TaqMan data (n = 3–4 for each
time point). Results shown
represent means or
mean ± standard deviation
(SD). P \ 0.05*, \0.01**,
\0.001***, \0.0001**** by 1
way-ANOVA with Bonferroni
post hoc test (TaqMan data,
each time point compared to
control (0 time point))
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the relative decrease in MVD after aflibercept treatment
(Fig. 1h, i; Table 1). After 24 h of aflibercept treatment,
the proportion of FITC-lectin positive BEC in C6 tumors
increased slightly to 66 % of all BECs, although the total
number of FITC-lectin positive BECs went down (to
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Fig. 3 Perfusion decreased in response to aflibercept treatment in
Colo205 and C6 tumors, but remained unchanged in HT1080 tumors. a–
c Representative images of vessel perfusion assessed by 2-dimensional
(2D) DCE-US in control and 24 h aflibercept-treated Colo205, C6 and
HT1080 tumors. Tumors are outlined in red. d–f Quantitative analysis of
vessel perfusion in control and 24 h aflibercept-treated Colo205 (n = 18
and 24, respectively), C6 (n = 8 and 12, respectively) and HT1080
tumors (n = 12 and 9, respectively) g Flow cytometry analysis of CD31-
positive blood vessel endothelial cells (BECs) in combination with the
intravenously injected perfusion marker FITC-lectin in control and 24 h
aflibercept-treated C6 (n = 10 each treatment group; n = 5 for
‘no-FITC’ group) and HT1080 tumors (n = 10 each treatment group;
n = 5 for ‘no-FITC’ group) as well as control-treated skin tissue (n = 5
each group). Shown are perfusion and flow cytometry results combined
from multiple experiments. Results shown represent mean ± standard
error of the mean (SEM). P \ 0.05*,\0.01**,\0.001***,\0.0001****
by Mann–Whitney test (tumor perfusion). Differences between
FITC-lectin positive BECs in ctrl versus aflibercept treated C6 or
HT1080 tumors and between ctrl treated C6 and ctrl treated HT1080
tumors were not statistically significant by Mann–Whitney test
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treatment, the proportion of FITC-lectin positive BEC also
increased slightly to 31 % of all BECs, whereas the total
number of BECs increased slightly (to 0.48 % of all cells)
(Fig. 3g; Table 1). Again, these findings are consistent
with perfusion changes seen by micro-ultrasound following
treatment of these tumors with aflibercept (Fig. 3e, f).
Thus, this flow cytometry-based analysis of tumor vessel
perfusion provides a powerful link between functional
perfusion assays and immunohistochemistry of tumor
blood vessels following anti-VEGF treatment.
Increased tumor hypoxia following treatment
with aflibercept
To determine whether the decreased tumor perfusion fol-
lowing aflibercept treatment resulted in tumor oxygenation
changes, we analyzed hypoxia in Colo205, C6, and
HT1080 tumors at 8, 24 and 72 h after aflibercept treat-
ment. Hypoxia was assessed by HypoxyProbe IHC
(Fig. 4a–c) as well as by analyzing the expression of
VEGF, a hypoxia regulated gene (Fig. 4g–i). Colo205 and
C6 tumors have hypoxic regions even under baseline
conditions, which become more pronounced upon afliber-
cept treatment starting at 8 h (Fig. 4a, b, d, e). The increase
in HypoxyProbe staining observed in C6 and Colo205
tumors after 24 h aflibercept treatment (Fig. 4d, e) corre-
sponded with decreased perfusion (Fig. 3d, e). In com-
parison, HT1080 tumors had little or no hypoxic regions at
baseline, and no increase in hypoxia at 72 h of treatment
with aflibercept (Fig. 4c, f), consistent with the unchanged
tumor perfusion (Fig. 3c, f). Similarly, expression of
VEGF progressively increased in C6 and Colo205 tumors,
whereas VEGF expression was unchanged in HT1080
tumors (Fig. 4g). Taken together, increased tumor hypoxia
correlated with decreased tumor perfusion.
Tumor perfusion changes correlated with long-term
response to aflibercept
The results from our analysis of three tumor types sug-
gested that rapid changes in tumor perfusion and/or
hypoxia correlated better with long-term tumor growth
response to aflibercept than did other parameters such as
changes in microvessel density or vascular gene expression
(Fig. 5a). To further assess whether tumor vascular perfu-
sion changes at 24 h after aflibercept treatment correlated
with long-term growth inhibition, we extended our analy-
ses to several additional tumor types (A431, 786-0, MMT,
LLC and PC-3 M) grown in immunocompromised SCID
mice. We also included a syngeneic model, LLC tumors
grown in C57Bl6 mice, to assess the effects of aflibercept
on tumor perfusion and growth in immunocompetent mice.
As expected, tumor growth inhibition in immunocompro-
mised mice did not correlate well with changes in tumor
vessel density (Fig. 5b, R2 = 0.09). In comparison, in this
larger sample including one syngeneic model, tumor
growth inhibition showed a correlation with changes in
tumor perfusion (Fig. 5c, R2 = 0.73).
Discussion
The search for early response and predictive biomarkers of
tumor response to anti-angiogenic agents has so far not
provided definitive candidates. While clinical studies have
sought such markers by sampling numerous growth factors
and cytokines, preclinical studies may be able to provide
more mechanism-based candidates and approaches. In this
study, we analyzed several tumors with a wide range of long-
term tumor growth responses to anti-VEGF therapy. Using
subcutaneous tumor models, we correlated early morpho-
logic and functional vascular changes following treatment
with aflibercept to long-term tumor growth inhibition (TGI).
We found that changes in tumor hypoxia and perfusion
correlated with long-term TGI, whereas changes in vascular
gene expression and MVD showed a poor correlation.
In early clinical analyses, MVD was proposed as a
prognostic indicator for disease stage, likelihood of
metastasis, recurrence, and survival in a range of tumor
types [26–28]. To date, however, neither baseline values,
nor treatment-related changes in MVD have proven useful
for evaluating or guiding anti-angiogenic treatments [29].
To extend the analysis of MVD, we identified a set of
endothelial cell marker genes, including Tie1, Pecam1,
Cdh5, Icam2 and Robo4 [20–22], which decreased fol-
lowing treatment with aflibercept. The timing and
Table 1 Flow cytometry analysis of all CD31-positive blood vessel endothelial cells (BECs) and perfused (FITC-lectin positive) BECs derived
from control and 24 h aflibercept-treated C6 and HT1080 tumors








% FITC-lectin ? BECs out of
total BECs
Control Aflibercept Control Aflibercept Control Aflibercept
C6 0.8 0.5 -37 0.43 0.33 -24 55 66
HT1080 2.2 1.6 -28 0.4 0.48 ?20 18 31
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magnitude of the decrease in these genes correlated well
with changes in tumor MVD. However, these gene
expression changes did not correlate with long-term TGI.
Further, changes in ‘acute’ gene expression, such as Esm1
and Nid2, which appear to reflect direct VEGF target genes
[30–32], similarly did not correlate with long-term TGI
following treatment with aflibercept. This latter finding
suggests that VEGF inhibition within a tumor is a neces-
sary but not sufficient determinant of efficacy of anti-
VEGF therapy.
Agents that target other angiogenic signaling pathways
further confound the attempts to correlate MVD, vascular
markers or indicators of VEGF signaling with anti-tumor
effects. For example, in pre-clinical models, blockade of
the angiogenic ligand Dll4 results in increased MVD [18,
33] and endothelial cell marker genes (data not shown), but
inhibits tumor growth, thus clearly showing that MVD
changes are not predictive of anti-angiogenic treatment
efficacy. In the case of Dll4 inhibition, the newly formed
tumor vascular structures are non-functional [18, 33].
ba c
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Fig. 4 Tissue oxygenation decreased in response to aflibercept
treatment in Colo205 and C6, but not in HT1080 tumors. a–
c Representative images of hypoxia assessed by HypoxyProbe IHC in
control and 24 h aflibercept-treated Colo205, C6 and HT1080 tumors
(80 lm gelatin sections). d-f) Quantitative analysis of hypoxia area
(%) in control and 8, 24 and 72 h aflibercept-treated Colo205, C6 and
HT1080 tumors (n = 4–5 each time point/tumor type). g–i TaqMan
analysis of the hypoxia responsive gene VEGF in Colo205, C6 and
HT1080 tumors after 8, 24 and 72 h aflibercept treatment (n = 3–4
each time point/tumor type). All experiments were repeated at least
twice; shown is an example experiment (n = 4–5 (hypoxia data) or
n = 3–4 (TaqMan data) for each time point). Results shown represent
means or mean ± standard deviation (SD). P \ 0.05*, \0.01**,
\0.001***, \0.0001**** by 1 way-ANOVA with Bonferroni post
hoc test (hypoxia IHC, each time point compared to control (0 time
point); TaqMan data, each time point compared to control (0 time
point))
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These findings, as well as our current results, emphasize
the concept that changes in tumor vessel functionality are
much more important for predicting tumor growth response
than changes in the number of vessels, their morphology or
their signaling profiles.
In preclinical models, intravenous injection of dyes like
FITC-lectin, Hoechst 33342 or DiOC7 prior to sacrifice has
frequently been used to distinguish perfused/functional
vessels from non-perfused vessels in tissue sections [7, 19,
34–36]. In addition, FITC-lectin or Hoechst 33342 have
been used with flow cytometry to detect perfused endo-
thelial cells or to assess the ratio of tumor cells close to
perfused blood vessels versus those further away [37, 38].
Our studies further validate the use of i.v. FITC-lectin
combined with CD31 flow cytometry, to distinguish endo-
thelial cells from perfused versus non-perfused vessels.
In clinical studies of VEGF blockade, DCE-MRI has
been used frequently to evaluate the functional microvas-
culature within tumors. In particular, decreases in Ktrans, a
volume transfer constant for contrast agent in blood/plasma
and the extravascular extracellular space, was shown to be
predictive of time to progression in liver cancer upon
VEGF blockade [39]. Similarly, changes in Ktrans allowed
the prediction of responses in glioblastoma patients treated
with bevacizumab and irinotecan [40]. In some preclinical
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Fig. 5 Changes in tumor
perfusion, but not in MVD, 24 h
after aflibercept treatment are
predictive of long-term tumor
growth inhibition. a Summary
of aflibercept effects on long-
term tumor growth and short-
term (up to 72 h) MVD, gene
expression, tumor perfusion and
hypoxia. b Poor correlation
between MVD changes (30 lm
OCT sections; n = 4–5 each
treatment group/tumor type) and
long-term TGI (n = 5–7 each
treatment group/tumor type) in
Colo205, C6, HT1080, MMT,
A431 and LLC tumors. c Good
correlation between tumor
perfusion changes (n = 7–24
each treatment group/tumor
type) and long-term TGI
(n = 5–7 each treatment group/
tumor type) in Colo205, C6,
HT1080, MMT, A431, LLC,
786-0 and PC-3 M tumors. All
experiments were repeated at
least twice; shown is an
example experiment for tumor
growth (n = 5–7) and vessel
density (n = 4–5) data along
with combined data for tumor
perfusion data (n = 7–24 each
treatment group/tumor type)
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Ktrans in response to VEGF blockade [41]. However, DCE-
MRI was not predictive of treatment efficacy upon anti-
angiogenic therapy in other cancers, such as NSCLC [42].
In an attempt to better predict anti-angiogenic efficacy,
DCE-MRI was combined with assessment of MVD and
plasma collagen IV levels shortly (24 h) after the start of
treatment. This ‘vascular normalization index’, was pre-
dictive of responsiveness to anti-angiogenic therapy in
glioma patients [43]. In a follow-up study, a prolonged
increase in tumor perfusion, as evidenced by DCE-MRI,
was associated with longer survival in glioma patients [44].
However, a recent positron emission tomography (PET)
imaging study reported a decrease in perfusion and
impaired docetaxel delivery after a single dose of bev-
acizumab in NSCLC patients [14], suggesting that vessel
normalization after VEGF blockade does not occur in
NSCLC. In another recent study, single-photon emission
computed tomography (SPECT) imaging revealed that
anti-VEGF treatment decreased tumor uptake of an anti-
Her2 antibody (trastuzumab) in preclinical breast cancer
models, thus further supporting that VEGF blockade results
in decreased tumor perfusion rather than vessel normali-
zation [15].
In addition to DCE-MRI, PET and SPECT, other
imaging modalities have been used to predict efficacy of
anti-angiogenic therapies. For example, dynamic contrast-
enhanced ultrasound (DCE-US) imaging has been used to
assess tumor perfusion before and after treatment of vari-
ous cancers with anti-angiogenic agents [45–47]. DCE-US
imaging typically uses gas-filled lipid-shell microbubbles
several micrometers in diameter as contrast agent [48].
DCE-US differs from DCE-MRI in that it solely assesses
changes in vascular perfusion, while DCE-MRI measures a
combination of blood flow through the vasculature as well
as tracer movement across the vessel wall [49]. Although
DCE-MRI and DCE-US appear to have predictive potential
in anti-angiogenic therapy, DCE-US may be less sensitive
to changes in tumor vascular permeability, and thus be
more robust for assessing changes in tumor perfusion.
Decreases in tumor perfusion can result in hypoxia, as
was observed after aflibercept treatment of sensitive
Colo205 and moderately responsive C6 tumors, but not in
resistant HT1080 tumors. These findings can be compared
to the vascular normalization hypothesis, which proposed
that tumor vessels remaining after anti-VEGF therapy
temporarily ‘normalize’ in terms of morphology and
functionality, resulting in increased tumor blood flow and
decreased hypoxia [10]. Other preclinical studies, however,
have shown that the anti-angiogenic agents DC101 and
AG-013736 induce decreased perfusion and increased
hypoxia [13, 35, 50]. Although it is well established that
human tumors are often hypoxic and poorly perfused [51],
direct measurement of tumor oxygenation before and after
VEGF blockade in patients is challenging. Instead, hypoxia
changes have been assessed indirectly. For example, bev-
acizumab treatment of RCC patients resulted in increased
tumor cell apoptosis, along with increased tumor cell
proliferation, which were hypothesized to be at least par-
tially due to increased blood flow and decreased hypoxia
[52].
The current study used various tumor models grown
subcutaneously in mice, a site that can be readily accessed
for micro-ultrasound studies of tumor perfusion. While the
vascular structures and responses to anti-angiogenic ther-
apies of such tumors may not fully reflect those of primary
and metastatic human tumors, the ability to directly mea-
sure tumor blood flow provides opportunities to identify
potential early response biomarkers that can be further
tested in orthotopic preclinical tumor models and in clinical
settings.
Early response biomarkers that can predict long-term
outcome to therapy would be powerful tools, and panels of
such potential biomarkers for anti-angiogenic therapies
have been explored. For example, changes in circulating
VEGF or PlGF levels, as well as tumor VEGF levels, were
thought to be predictive, but to date have not shown to be
well correlated with outcome [53]. In the current preclin-
ical study, decreases in tumor perfusion and increases in
hypoxia following treatment of subcutaneous xenograft and
syngeneic models with aflibercept correlated with long-
term TGI. Our results suggest that perfusion changes, as
measured by DCE-US, shortly after treatment with VEGF
inhibitors or possibly other anti-angiogenic therapies, could
potentially be used as an early response biomarker to assess
treatment efficacy.
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